YAP1 and cancer: Lin et al. [30] unveiled the synthetic lethality of combined suppression of YAP1 (a key downstream effector of HIPPO pathway) and BRAF inhibitors as a promising strategy to enhance treatment response in human cancers with oncogenic activation of BRAF-MEK-ERK signaling pathway.